Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab

NCT00332163 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00332163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00332163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
September 30, 2008
Enrollment
95 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, colorectal cancer, metastatic colorectal cancer, skin rash, skin toxicities